Comprehensive analysis of oncogenic signatures and consequent repurposed drugs in TMPRSS2:ERG fusion-positive prostate cancer

Clin Transl Med. 2021 May;11(5):e420. doi: 10.1002/ctm2.420.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Drug Repositioning*
  • Gene Expression Profiling*
  • Gene Fusion*
  • Humans
  • Male
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / genetics*
  • Serine Endopeptidases / genetics*
  • Transcriptional Regulator ERG / genetics

Substances

  • Antineoplastic Agents
  • ERG protein, human
  • Transcriptional Regulator ERG
  • Serine Endopeptidases
  • TMPRSS2 protein, human